Lobular Breast Carcinoma
Associated Genetic Biomarkers
NCI Definition: An adenocarcinoma of the breast arising from the lobules. This is a relatively uncommon carcinoma, represents approximately 10% of the breast adenocarcinomas and is often bilateral or multifocal. 
Lobular breast carcinomas most frequently harbor alterations in CDH1, PIK3CA, TP53, CCND1, and ERBB2 .
PIK3CA Mutation, CDH1fs, CDH1 Mutation, PIK3CA Codon 1047 Missense, and PIK3CA H1047R are the most common alterations in lobular breast carcinoma .
There are 4 clinical trials for lobular breast carcinoma, of which 3 are open and 1 is completed or closed. Of the trials that contain lobular breast carcinoma as an inclusion criterion, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open).
HER2, ER, and PR are the most frequent gene inclusion criteria for lobular breast carcinoma clinical trials .
Crizotinib, fulvestrant, and lenalidomide are the most common interventions in lobular breast carcinoma clinical trials.
Significant Genes in Lobular Breast Carcinoma
CDH1 is altered in 67.92% of lobular breast carcinoma patients .
CDH1 is an inclusion eligibility criterion in 1 clinical trial for lobular breast carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDH1 status and lobular breast carcinoma as inclusion criteria, 1 is phase 2 (1 open) .
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.